{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-242007","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2025-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.673867+00:00","generated_at":"2026-05-17T03:25:29.504980+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"confidence":"high","headline":"Sensei Biotherapeutics reports 50% 6-month PFS for solnerstotug in PD-(L)1 resistant tumors at ESMO 2025","bullets":["6-month PFS of 50% in 15 mg/kg dose cohort in PD-(L)1 resistant patients vs historical ~10-20% for docetaxel.","Complete response in Merkel cell carcinoma patient; duration of response 54+ weeks. Four of six responders had late onset responses (18-54 weeks).","Favorable safety: only six mild Grade 1 CRS events across all 98 patients; no new safety signals.","Phase 2 studies planned in 2L NSCLC and Merkel cell carcinoma in 2026, subject to FDA feedback and capital raise."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-242007","json":"https://secwatch.observer/filing/0001193125-25-242007.json","markdown":"https://secwatch.observer/filing/0001193125-25-242007.md","text":"https://secwatch.observer/filing/0001193125-25-242007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312525242007/0001193125-25-242007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312525242007/d223319d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:25:29.504980+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}